SHAMROCK INDUSTRIAL COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.13 INR | -4.94% |
|
-0.25% | +49.20% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 0.97 80.61 1.32 | Sales 2023 | - | Capitalization | 19.96M 1.67B 27.29M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -167M -2.73M | Net income 2023 | -1M -83.49M -1.37M | EV / Sales 2022 | 29,453,449 x |
| Net cash position 2022 | 10.03M 837M 13.71M | Net cash position 2023 | 9.68M 808M 13.23M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-18.5
x | P/E ratio 2023 |
-15.3
x | Employees | 1 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 53.41% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.94% | ||
| 1 week | -0.25% | ||
| Current month | -6.98% | ||
| 1 month | +6.68% | ||
| 3 months | +48.29% | ||
| 6 months | +152.71% | ||
| Current year | +49.20% |
1 week
11.56
12.76
1 month
10.6513.83
Current year
7.2713.83
1 year
3.3413.83
3 years
3.1613.83
5 years
3.1613.83
10 years
3.1613.83
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | 18-06-18 | |
Kalpesh Khokhani
CHM | Chairman | 54 | 94-12-31 |
| Compliance Officer | - | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kalpesh Khokhani
CHM | Chairman | 54 | 94-12-31 |
Kamlesh Khokhani
CEO | Chief Executive Officer | 52 | 94-09-30 |
| Director of Finance/CFO | - | 18-06-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 12.13 | -4.94% | 1,000 |
| 24-05-09 | 12.76 | 0.00% | 530 |
| 24-05-06 | 12.76 | +4.93% | 83 |
| 24-05-03 | 12.16 | -1.86% | 981 |
Delayed Quote Bombay S.E., May 10, 2024 at 06:00 am
More quotes
Shamrock Industrial Company Limited (SICL) is an India-based company, which is a trader of pharmaceuticals products. The Company offers a range of manufacturing of pharmaceuticals and drugs products, and allied business activities. The Company's division include Bulk, Pharmaceuticals and Chemicals Division (BPC), Medivet, Research and Development, ERP, Nviro Chemstock and Nutrasciences. BPC comprises of manufacturing and contract manufacturing of active pharmaceutical ingredients (APIs), advance intermediates, intermediates and fine chemicals. It consists of manufacturing, contract manufacturing and outsourcing products. Medivet division's product range comprise of potent and healthy anthelmintic range. Nviro Chemstock is engaged in exports contract manufacturing API, Intermediates and fine chemicals. The Company's customer portfolio consists of generic API producers, multinational companies, finished formulations manufacturers, and distributers.
Sector
Pharmaceuticals
Calendar
2024-05-29
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +49.20% | 788K | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- SHAMROIN Stock
